Application of hepatobiliary-specific MRI contrast agent Gd-EOB-DTPA in preoperative evaluation of hepatobiliary patients

Jiang JiaYun; Li XueSong; Ma KuanSheng

doi:10.3969/j.issn.1001-5256.2015.06.042

Issue 6

Jun. 2015

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2015 > 31(6): 996-999

PDF( 1422 KB)

Application of hepatobiliary-specific MRI contrast agent Gd-EOB-DTPA in preoperative evaluation of hepatobiliary patients

DOI: 10.3969/j.issn.1001-5256.2015.06.042

Institute of Hepatobiliary Surgery,Southwest Hospital,Third Military Medical University

Research funding:

Received Date: 2014-10-29
Published Date: 2015-06-20

Abstract

Abstract

Gd- EOB- DTPA,a newly applicable hepatocyte- specific contrast agent,is excreted through the biliary tract and the kidney,showing the characteristics of nonspecific extracellular contrast agent and hepatocyte- specific contrast agent. It can provide both dynamic and hepatobiliary images and has been rapidly accepted by clinicians for the diagnosis of liver lesions and preoperative evaluation. Gd- EOB-DTPA can fulfill hepatic perfusion imaging,cholangiography,detection and characterization of focal liver lesions,and evaluation of liver function within the same examination in a relatively short time window. A large number of domestic and foreign studies have confirmed that hepatobiliary- specific contrast- enhanced MRI is significantly superior to MRI scan,contrast- enhanced CT,and ultrasound in diagnosing hepatocellular carcinoma,especially small hepatocellular carcinoma. The features of Gd- EOB- DTPA and its current status and prospect of application in the preoperative evaluation of hepatocellular carcinoma are reviewed in this article.
- liver neoplasms,
- magetic resonance imaging,
- contrast media,
- Gd-EOB-DTPA,
- review

FullText(HTML)

References(22)

References

[1]PURYSKO AS,REMER EM,VENIERO JC.Focal liver lesion detection and characterization with GD-EOB-DTPA[J].Clin Radiol,2011,66(7):673-684.

[2]FRERICKS BB,LODDENKEMPER C,HUPPERTZ A,et al.Qualitative and quantitative evaluation of hepatocellular carcinoma and cirrhotic liver enhancement using Gd-EOB-DTPA[J].AJR Am J Roentgenol,2009,193(4):1053-1060.

[3]CHANYAPUTHIPONG J,LOW SC,CHOW PK.Gadoxetate acid-Enhanced MR imaging for HCC:a review for clinicians[J].Int J Hepatol,2011,2011:489342.

[5]GOLFIERI R,RENZULLI M,LUCIDI V,et al.Contribution of the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI to Dynamic MRI in the detection of hypovascular small(≤2 cm)HCC in cirrhosis[J].Eur Radiol,2011,21(6):1233-1242.

[6]LEE JH,LEE JM,KIM SJ,et al.Enhancement patterns of hepatocellular carcinomas on multiphasic multidetector row CT:comparison with pathological differentiation[J].Br J Radiol,2012,85(1017):e573-e583.

[7]LEE SA,LEE CH,JUNG WY,et al.Paradoxical high signal intensity of hepatocellular carcinoma in the hepatobiliary phase of Gd-EOB-DTPA enhanced MRI:initial experience[J].Magn Reson Imaging,2011,29(1):83-90.

[8]NARITA M,HATANO E,ARIZONO S,et al.Expression of OATP1B3determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma[J].J Gastroenterol,2009,44(7):793-798.

[9]ZECH CJ,GRAZIOLI L,JONAS E,et al.Health-economic evaluation of three imaging strategies in patients with suspected colorectal liver metastases:Gd-EOB-DTPA-enhanced MRI vs.extracellular contrast media-enhanced MRI and 3-phase MDCT in Germany,Italy and Sweden[J].Eur Radiol,2009,19(Suppl 3):s753-s763.

[10]RIMOLA J,FORNER A,REIG M,et al.Cholangiocarcinoma in cirrhosis:Absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma[J].Hepatology,2009,50(3):791-798.

[11]DOO KW,LEE CH,CHOI JW,et al.“Pseudo washout”sign in high-flow hepatic hemangioma on gadoxetic acid contrast-en-hanced MRI mimicking hypervascular tumor[J].AJR Am J Roentgenol,2009,193(6):w490-w496.

[12]ZECH CJ,GRAZIOLI L,BREUER J,et al.Diagnostic performance and description of morphological features of focal nodular hyperplasia in Gd-EOB-DTPA-enhanced liver magnetic resonance imaging:results of a multicenter trial[J].Invest Radiol,2008,43(7):504-511.

[13]TANIMOTO A,MIN LEE J,MURAKAMI T,et al.Consensus report of the 2nd International Forum for Liver MRI[J].Eur Radiol,2009,19(Suppl 5):975-989.

[14]van BEERS BE,PASTOR CM,HUSSAIN HK.Primovist,Eovist:what to expect?[J].J Hepatol,2012,57(2):421-429.

[15]LEE NK,KIM S,LEE JW,et al.Biliary MR imaging with GdEOB-DTPA and its clinical applications[J].Radiographics,2009,29(6):1707-1724.

[16]LLADL,FIGUERAS J,MEMBA R,et al.Is MELD really the definitive score for liver allocation?[J].Liver Transpl,2002,8(9):795-798.

[17]LI JF,HU YQ,HE SQ.Research progress in evaluation of liver reserve founction[J].China Med Heral,2013,10(24):41-44.(in Chinese)李江发,胡虞乾,何松青.肝脏储备功能评估的研究进展[J].中国医药导报,2013,10(24):41-44.

[18]TANG F,LIU H.Research developrnent of Gd-EOB-DTPA in evaluation of liver function[J].Chin J Med Imaging Tednol,2014,30(6):939-942.(in Chinese)唐菲,刘辉.新型磁共振对比剂Gd-EOB-DTPA用于评估肝功能研究进展[J].中国医学影像技术,2014,30(6):939-942.

[19]RYEOM H,KIM S,KIM J,et al.Quantitative evaluation of liver function with MRI Using Gd-EOB-DTPA[J].Korean J Radiol,2004,5(4):231-239.

[20]JIANG J,YE JJ,LIU GY,et al.Visualization of the biliary ducts on contrast enhanced MR chlangiography with Gd-EOB-DTPA:reloation with liver function in patients with liver cirrhosis[J].Chin J Med Imaging Tednol,2013,29(5):765-769.(in Chinese)蒋健,叶健军,刘光耀,等.Gd-EOB-DTPA增强MR胆管成像对胆管的显示与肝硬化患者肝功能的关系[J].中国医学影像技术,2013,29(5):765-769.

[21]KATSUBE T,OKADA M,KUMANO S,et al.Estimation of liver function using T1 mapping on Gd-EOB-DTPA-enhanced magnetic resonance imaging[J].Invest Radiol,2011,46(4):277-283.

[22]YAMADA A,HARA T,LI F,et al.Quantitative evaluation of liver function with use of gadoxetate disodium-enhanced MR imaging[J].Radiology,2011,260(3):727-733.

[23]TAJIMA T,TAKAO H,AKAI H,et al.Relationship between liver function and liver signal intensity in hepatobiliary phase of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging[J].J Comput Assist Tomogr,2010,34(3):362-366.

Relative Articles

[1]	Yunchong WU, Yanyan YANG, Chuan LI, Xiaohuan WU, Shide LIN. Role of inflammatory cytokines in disorder of glucose metabolism in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2024, 40(9): 1886-1890. doi: 10.12449/JCH240926
[2]	Yifan YANG, Wanwei DU, Xia WANG, Guangde YANG, Li LI, Juanjuan FU, Xiucheng PAN. Effect of the STING pathway on inflammatory cytokine secretion and phagocytosis by peripheral blood monocytes in patients with hepatitis B cirrhosis[J]. Journal of Clinical Hepatology, 2023, 39(9): 2117-2121. doi: 10.3969/j.issn.1001-5256.2023.09.013
[3]	Hepatology｜Macrophage-specific fibroblast growth factor 12 promotes liver fibrosis progression in mice[J]. Journal of Clinical Hepatology, 2022, 38(8): 1885-1885. doi: 10.3969/j.issn.1001-5256.2022.08.gwjpwzjj2
[4]	Zixiang GAO, Zhongliang SHEN, Jing LIU, Youhua XIE. Research advances in cytokines in the treatment of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2022, 38(8): 1710-1715. doi: 10.3969/j.issn.1001-5256.2022.08.002
[5]	Xiaofei YANG, Linxu WANG, Changxing HUANG, Jie DONG, Haifeng HU, Zhanhu BI, Jianqi LIAN, Ye ZHANG. Mechanism of gamma-chain cytokines in regulating the expression of T-cell immunoglobulin and mucin domain-containing molecule 3 in CD8⁺ T cells of chronic hepatitis B patients[J]. Journal of Clinical Hepatology, 2021, 37(5): 1059-1064. doi: 10.3969/j.issn.1001-5256.2021.05.017
[6]	Leigang JIN, Leiluo GENG, Aimin XU. Current status and perspectives of fibroblast growth factor 21 in nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(6): 1262-1267. doi: 10.3969/j.issn.1001-5256.2021.06.006
[7]	Zhang Yu, Shao YueMing, Qin TingTing, Yin Xin, Wen XiaoYu. Current research status and application value of cytokines in drug-induced liver injury[J]. Journal of Clinical Hepatology, 2020, 36(8): 1883-1886. doi: 10.3969/j.issn.1001-5256.2020.08.045
[8]	Gao Yi, Liang ZhiJun, Fu Jian. Influence of sofosbuvir-based antiviral therapy on the expression profile of cytokines and chemokines in patients with chronic hepatitis C[J]. Journal of Clinical Hepatology, 2019, 35(10): 2200-2204. doi: 10.3969/j.issn.1001-5256.2019.10.014
[9]	Wei XinHuan, Liu YaLi, Zhang Jing, Lin Wei. Expression and significance of cytokines in children with acute hepatitis A[J]. Journal of Clinical Hepatology, 2019, 35(9): 1942-1945. doi: 10.3969/j.issn.1001-5256.2019.09.011
[10]	Xiang Jiao, Jia XiaoDong, Lu ShanShan, Wu DaWei, Zhang Ting, Dong JinKe, Huang JiaGan, Li YinYin, Yang Bin, Xu Yong, Dong Zheng, Lu Ying, Zeng Zhen, Lu YinYing. Effect of cryoablation versus microwave ablation on clinical indices and cytokines in patients with hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2019, 35(8): 1728-1733. doi: 10.3969/j.issn.1001-5256.2019.08.016
[11]	Sheng QingShou, Lai GuoQuan, Yu XueJing, Wei Cui. The role of traditional Chinese medicine in regulating cytokines associated with liver fibrosis[J]. Journal of Clinical Hepatology, 2018, 34(12): 2677-2680. doi: 10.3969/j.issn.1001-5256.2018.12.037
[12]	Li ShuHuan, Han JiWu. Inhibitory effect of fibroblast growth factor-21 on the carcinogenesis of L02 cells induced by diethylnitrosamine[J]. Journal of Clinical Hepatology, 2018, 34(2): 321-326. doi: 10.3969/j.issn.1001-5256.2018.02.020
[13]	Guo FeiBo, Wu JunZhu, Ai LiMing, Song Ying. Clinical significance of Th17/Treg and associated cytokines in peripheral blood in chronic hepatitis C patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2017, 33(3): 479-484. doi: 10.3969/j.issn.1001-5256.2017.03.017
[14]	Zhang Ning, Guo ZhenZhong, Cheng Yan. Effect of dexmedetomidine on liver function, cytokine levels, and oxidative stress in patients undergoing hepatolobectomy[J]. Journal of Clinical Hepatology, 2017, 33(3): 507-511. doi: 10.3969/j.issn.1001-5256.2017.03.022
[16]	Shi GuangYing, Ma XiaoYuan, Xie JingDong. Changes in T lymphocyte subsets and cytokines in peripheral blood of patients with primary biliary cirrhosis after treatment with different doses of ursodeoxycholic acid[J]. Journal of Clinical Hepatology, 2015, 31(9): 1447-1451. doi: 10.3969/j.issn.1001-5256.2015.09.020
[17]	Wang ShaoYang, Lin TaoFa, Liu HaiZhou, Ma WeiMin, Xie ZhiHong. A clinical study of autologous cytokine-induced killer cells in treatment of patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2015, 31(4): 530-533. doi: 10.3969/j.issn.1001-5256.2015.04.013
[18]	Zhang LiangJie, Chen HuiJuan, Zhao ShouSong. Effects of artificial liver plasma exchange on cytokines in patients with liver failure[J]. Journal of Clinical Hepatology, 2015, 31(4): 578-581. doi: 10.3969/j.issn.1001-5256.2015.04.024
[19]	Chen WeiHong, Chen Yan. Serum Th1 /Th2 cytokine levels and their clinical significance in patients with alcoholic liver cirrhosis[J]. Journal of Clinical Hepatology, 2014, 30(7): 631-635. doi: 10.3969/j.issn.1001-5256.2014.07.014
[20]	Zhou Jian, Wan Hong. Relationship between changes in serum cytokine levels after artificial liver therapy and clinical prognosis in patients with liver failure[J]. Journal of Clinical Hepatology, 2013, 29(7): 535-537. doi: 1001-5256 (2013) 07-0535-03

Supplements(0)

Cited By

Cited by

Periodical cited type(3)

1.	张艳培，梁健，邓鑫，梁明坤，张冰冰，徐粤娟. 浅析肝纤维化发生机制. 大众科技. 2021(02): 41-44+12 .
2.	曾静，熊庆，张丽丽，袁娟，何莹，邱黎菲. SPACE肽修饰成纤维细胞生长因子21的制备及对小鼠皮肤瘢痕形成的抑制作用. 中国免疫学杂志. 2021(11): 1308-1312 .
3.	唐青蓝，李红梅，张礼林，王玉丰，颜礼完，周君. 小鼠FGF21基因克隆及his-mFGF21融合蛋白的诱导表达. 贵州医科大学学报. 2019(05): 552-556 .

Other cited types(0)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2708) PDF downloads(632)

Application of hepatobiliary-specific MRI contrast agent Gd-EOB-DTPA in preoperative evaluation of hepatobiliary patients

DOI: 10.3969/j.issn.1001-5256.2015.06.042